andrew armstrong, md, offers opinion on androgen receptor inhibitors
Published 5 years ago • 28 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:07
andrew armstrong, md, presents an overview of the arches trial in mhspc
-
1:05
andrew armstrong, md, explains whether arv-7 is predictive of response to taxanes in mpc patients
-
1:00
dr. armstrong on the utility of pamiparib and other parp inhibitors in prostate cancer
-
1:18
andrew armstrong, md, discusses the phase 2 stream study in pre-metastatic prostate cancer
-
1:29
andrew armstrong, md, provides insight as to genetic testing to be conducted in a patient with mpc
-
11:02
risk-adapted treatment monitoring in mcrpc apccc 2022
-
29:37
david armstrong's materialist theory of mind
-
24:13
enzalutamide: monotherapy and combination therapy - andrew j. armstrong
-
1:05
dr. agarwal on androgen receptor inhibitors for prostate cancer
-
2:09
andrew armstrong, md, on determining treatment of prostate cancer with dna repair markers
-
1:01
dr. armstrong discusses ar-v7 testing in prostate cancer
-
19:29
first line therapy combination in men with mcrpc by andrew armstrong
-
0:57
dr. armstrong on the utility of parp inhibitors in mutated prostate cancer
-
1:14
dr. armstrong on precision medicine for metastatic prostate cancer
-
1:05
dr. shore on challenges with adt in recurrent prostate cancer
-
1:17
andrew hertler, md, facp, considers the benefits of participating in an aco
-
1:18
dr. armstrong discusses arches trial in prostate cancer
-
9:53
dr. andrew armstrong on precision medicine approaches in advanced prostate cancer
-
1:00
dr. wise on ar-directed therapy for prostate cancer
-
0:51
os sensitivity analysis of darolutamide, docetaxel and adt in arasens
-
1:20
dr. armstrong discusses hereditary prostate cancer
-
4:19
the biology of prostate cancer